JP2024535853A5 - - Google Patents
Info
- Publication number
- JP2024535853A5 JP2024535853A5 JP2024516885A JP2024516885A JP2024535853A5 JP 2024535853 A5 JP2024535853 A5 JP 2024535853A5 JP 2024516885 A JP2024516885 A JP 2024516885A JP 2024516885 A JP2024516885 A JP 2024516885A JP 2024535853 A5 JP2024535853 A5 JP 2024535853A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- tap
- seq
- cell
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163261315P | 2021-09-17 | 2021-09-17 | |
| US63/261,315 | 2021-09-17 | ||
| PCT/CA2022/051377 WO2023039673A1 (en) | 2021-09-17 | 2022-09-16 | Novel tumor-specific antigens for colorectal cancer and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024535853A JP2024535853A (ja) | 2024-10-02 |
| JP2024535853A5 true JP2024535853A5 (enExample) | 2025-09-19 |
Family
ID=85601865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516885A Pending JP2024535853A (ja) | 2021-09-17 | 2022-09-16 | 結腸直腸がんに対する新規の腫瘍特異的抗原及びそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250136937A1 (enExample) |
| EP (1) | EP4402159A4 (enExample) |
| JP (1) | JP2024535853A (enExample) |
| KR (1) | KR20240058179A (enExample) |
| CN (1) | CN118234745A (enExample) |
| AU (1) | AU2022348080A1 (enExample) |
| CA (1) | CA3231441A1 (enExample) |
| IL (1) | IL311408A (enExample) |
| MX (1) | MX2024003142A (enExample) |
| WO (1) | WO2023039673A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202241925A (zh) | 2021-01-15 | 2022-11-01 | 德商英麥提克生物技術股份有限公司 | 用於不同類型癌症免疫治療的ｈｌａ展示肽 |
| CN121182806B (zh) * | 2025-09-23 | 2026-06-19 | 谈高 | 特异性靶向Treg下调MHC-I基因的shRNA、纳米颗粒及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| DE102018107224A1 (de) * | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| MX2021002333A (es) * | 2018-08-30 | 2021-04-28 | Univ Montreal | Metodo basado en proteogenomica para identificar antigenos especificos de tumores. |
| US12394502B2 (en) * | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
-
2022
- 2022-09-16 US US18/692,730 patent/US20250136937A1/en active Pending
- 2022-09-16 CA CA3231441A patent/CA3231441A1/en active Pending
- 2022-09-16 EP EP22868501.2A patent/EP4402159A4/en active Pending
- 2022-09-16 AU AU2022348080A patent/AU2022348080A1/en active Pending
- 2022-09-16 IL IL311408A patent/IL311408A/en unknown
- 2022-09-16 KR KR1020247012639A patent/KR20240058179A/ko active Pending
- 2022-09-16 WO PCT/CA2022/051377 patent/WO2023039673A1/en not_active Ceased
- 2022-09-16 CN CN202280075075.9A patent/CN118234745A/zh active Pending
- 2022-09-16 JP JP2024516885A patent/JP2024535853A/ja active Pending
- 2022-09-16 MX MX2024003142A patent/MX2024003142A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023521219A5 (enExample) | ||
| Xiao et al. | CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy | |
| JP6882178B2 (ja) | ワクチン接種に有用なｔ細胞エピトープの予測 | |
| WO2021108661A2 (en) | Chimeric antigen receptors and uses thereof | |
| JP2021522820A5 (enExample) | ||
| JP2022512912A5 (enExample) | ||
| JP2019513373A5 (enExample) | ||
| CN112533630B (zh) | 用于癌症的个体化疫苗 | |
| WO2015172339A1 (zh) | 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞 | |
| Kottke et al. | Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy | |
| JP2022523554A5 (enExample) | ||
| JP2022524994A5 (enExample) | ||
| JP2021525549A5 (enExample) | ||
| JP2020533962A5 (enExample) | ||
| JP2022523971A5 (enExample) | ||
| CA3236106A1 (en) | Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies | |
| JP2022523553A5 (enExample) | ||
| JP2022524992A5 (enExample) | ||
| JP2023518396A5 (enExample) | ||
| Han et al. | Regulation of the translation activity of antigen-specific mRNA is responsible for antigen loss and tumor immune escape in a HER2-expressing tumor model | |
| CN114599400A (zh) | 用于治疗癌症的医药、组合医药、医药组合物、免疫应答细胞、核酸递送介质和制品 | |
| JP2023521436A5 (enExample) | ||
| JP2022543059A5 (enExample) | ||
| WO2022235975A2 (en) | Sirna constructs for inhibiting gene expression in targeted cancer cells | |
| JP2021517454A5 (enExample) |